Empagliflozin

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

97 API Suppliers, 35 USDMF, 10 EU WC, 31 KDMF, 20 NDC API, 79 Listed Suppliers

DEVELOPMENTS

50 Drug(s) in Development

50 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Imports

INTERMEDIATES

89 Suppliers

89 Suppliers

DOSSIERs // Finished Dosage Formulations

132 Dossiers, 50 FDA Orange Book, 30 Europe, 8 Canada, 6 Australia, 8 South Africa, 30 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 10MG, TABLET;ORAL - 25MG, TABLET;ORAL - 10MG;5MG, TABLET;ORAL - 25MG;5MG

TABLET;ORAL - 10MG
TABLET;ORAL - 25MG
TABLET;ORAL - 10MG;5MG
TABLET;ORAL - 25MG;5MG

GLOBAL SALES INFORMATION

8 US Medicaid Prescriptions, 30 Finished Drug Prices

MARKET PLACE

40 APIs, 13 DOSSIERS // FDF, 1 Intermediates

PATENTS

316 US Patents, 24 US Exclusivities, 4 Health Canada Patents

ANALYTICAL SOLUTION(s)

13 Other Ref. Standards

13 Other Ref. Standards

DIGITAL CONTENT

10 Data Compilations & Company Tracker #PharmaFlow, 280 News, 1 Monthly Stock Recap #PipelineProspector

List of Suppliers

Full Screen View

Reset Filter

Price Info

Tianjin Hankang Pharmaceutical Biot...

Tianjin Hankang is a research-driven API manufacturer with over 90 new drug clinical approvals.

Contact Supplier

China

Virtual Booth

Digital Content

(3R,4S,5R,6R)-3,4,5-Tris((trimethylsilyl)oxy)-6-(((trim...

PDF Supplier PDF

URL Supplier Web Content

CAS Number

32384-65-9

End Use API

Empagliflozin

About The Company

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enter...

Established in 1999, Hankang Pharmaceutical Group stands as a prominent CRO-CDMO integrated service enterprise in China. Focused on generic drugs while venturing into innovative ones, the group is dedicated to offering comprehensive solutions to the industry. Presently, Hankang has crafted over 200 varieties for 600+ domestic and international companies, serving 10+ innovative drugs. It has successfully developed more than 10 initial generic drugs, with over 20 varieties endorsed by the top three domestic companies and 30 exceeding a 100 million output value.